Compare Danaher Corporation (DHR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Danaher Corporation trades at $217.88 (market cap $153.60B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Danaher Corporation is far larger — about 66.5× Recursion Pharmaceuticals Inc's market cap, and Danaher Corporation pays a 0.73% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| DHR | RXRX | |
|---|---|---|
Market Cap | $153.60B | $2.31B |
Volume | 3,974,063 | 40,478,768 |
Sector | Health | Health |
52-Week High | $242.05 | $6.79 |
52-Week Low | $161.91 | $2.84 |
Typical Hold Time | 69 Days | 22 Days |
Enterprise Value | $175.81B | $1.83B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
